Last reviewed · How we verify
NCT06980753
Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders
NA trial testing Participants will use the biossensor for 48 h in Cushing Syndrome in 246 participants. Not yet recruiting.
1 November 2025
Quick facts
| Lead sponsor | University of Sao Paulo General Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 246 |
| Start date | 1 June 2025 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Participants will use the biossensor for 48 h
Conditions studied
- Cushing Syndrome — all drugs for Cushing Syndrome →
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
- Adrenal Insufficiency — all drugs for Adrenal Insufficiency →
Sponsor
University of Sao Paulo General Hospital
Who can join
18 and older, any sex, with Cushing Syndrome or Primary Aldosteronism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this project is to provide novel technology that will pave the way from the present single-point (analogue) endocrinology towards continuous cortisol and aldosterone monitoring with full time resolution. Current endocrine practice relies on occasional and often random determination of hormone level or functional tests that require a clinical setting. These measurements include sample extraction and analysis in a clinical laboratory rendering such tests laborious and expensive. Most importantly, through the individual variations of hormone oscillation and spatiotemporal distribution of hormones, infrequent hormone measurements have limited diagnostic and prognostic value as the dynamic changes are not captured and relevant intra-individual variability occurs. A requirement for this vision are sensing solutions capable to track hormone dynamics over prolonged periods at high patient comfort (e.g., at home), as targeted by this research proposal. This project has the overarching goals of (1) establishing dynamic interstitial aldosterone and cortisol monitoring as reliable diagnostic tool for cortisol and aldosterone excess or deficiency, and (2) develop a wearable molecular sensing device to detect them accurately.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Designing the Future of Biosensing: Advances in Aptamer Discovery, Computational Modeling, and Diagnostic Applications.
Jesky RG, Lo LHY, Siu RHP, Tanner JA. · · 2025 · PMID 41149291 · DOI 10.3390/bios15100637
Verify or expand the search:
- PubMed search for NCT06980753
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cushing Syndrome
Currently open trials in the same condition.
- NCT07168122 — Establishment and Clinical Application of Reference Intervals of Salivary Cortisol · recruiting
- NCT06635629 — Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome · Phase 2 · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06250699 — A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery · NA · recruiting
- NCT05911620 — Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hyperco · NA · recruiting
Other University of Sao Paulo General Hospital trials
Trials by the same sponsor.
- NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
- NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
- NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
- NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
- NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06980753 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
- Last refreshed: 20 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06980753.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing